Why the study?
What are the differences in clinical outcomes and arrhythmic risk among patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy?
What are the differences in clinical outcomes and arrhythmic risk among patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy?
Nonobstructive HCM requires detailed sudden cardiac death risk stratification due to higher arrhythmic risk, while labile HCM may be managed less aggressively.
Nonobstructive HCM was associated with higher arrhythmic risk; hypothesis-generating for refined SCD stratification pending prospective validation.
Nonobstructive HCM carries notable morbidity, including a higher arrhythmic risk than the other HCM groups. Patients with labile HCM have a relatively benign clinical course. Our data suggest detailed sudden cardiac death risk stratification in nonobstructive HCM and monitoring with less aggressive management in labile HCM.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2018) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: